Last reviewed · How we verify
Aflibercept Intravitreous Injection
Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endothelial cell receptors and reducing abnormal blood vessel growth in the eye.
Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endothelial cell receptors and reducing abnormal blood vessel growth in the eye. Used for Wet age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).
At a glance
| Generic name | Aflibercept Intravitreous Injection |
|---|---|
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | VEGF inhibitor / Soluble decoy receptor |
| Target | VEGF-A, VEGF-B, PlGF (placental growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human immunoglobulin G. By sequestering VEGF-A, VEGF-B, and PlGF in the vitreous, it inhibits pathological neovascularization and vascular permeability that characterize retinal diseases. This mechanism reduces fluid accumulation and abnormal vessel formation in conditions like wet age-related macular degeneration and diabetic macular edema.
Approved indications
- Wet age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
- Myopic choroidal neovascularization
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (PHASE4)
- A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) (PHASE4)
- A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) (PHASE2)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (PHASE3)
- DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (PHASE3)
- Anti-VEGF Treatment for Prevention of PDR/DME (PHASE3)
- Anti-VEGF vs. Prompt Vitrectomy for VH From PDR (PHASE2, PHASE3)
- Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: